BioSpace News Archive

Policy

Lykos’ MDMA-Assisted Therapy Faces Landmark Adcomm

Experts say approval of Lykos Therapeutics’ MDMA capsules for post-traumatic stress disorder would open the door to further research into psychedelic-assisted therapies.

May 29, 2024
·
6 min read
·
Gail Dutton
Drug Development

Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters

Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 billion in value by the early 2030s, according to analysts cited by Reuters.

May 29, 2024
·
3 min read
·
Tristan Manalac
FDA

Amgen Wins FDA Approval for First Biosimilar to AstraZeneca’s Soliris

Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

May 29, 2024
·
2 min read
·
Tristan Manalac
Deals

Merck’s Potential $3B EyeBio Acquisition Puts Drugmaker Back in Ophthalmology

Merck on Wednesday announced a deal worth $3 billion to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the pharma’s return to the ophthalmology space after nearly a decade.

May 29, 2024
·
2 min read
·
Tristan Manalac
Drug Development

AstraZeneca Touts Early-Stage Results for Oral PCSK9 Inhibitor

AstraZeneca on Wednesday unveiled Phase I results for its PCSK9 inhibitor, acquired from Dogma Therapeutics in 2020, which when combined with a statin reduced LDL-C levels in patients with high “bad” cholesterol.

May 29, 2024
·
2 min read
·
Tyler Patchen
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion

In this second episode of our collaboration with DIA, we discuss the challenging, collaborative process of regulating advanced therapy product development with guests James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.

May 29, 2024
·
1 min read
Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises

As funding dipped, early-stage biotechs began tying CEO package components, including salary increases and equity topoffs, to raising capital.

May 29, 2024
·
4 min read
·
Angela Gabriel
Drug Development

J&J Scores Phase III Victory in Major Depressive Disorder

Johnson & Johnson on Wednesday reported late-stage trial data showing its first-in-class orexin receptor antagonist reduced major depressive disorder symptoms as an adjunctive treatment in patients with insomnia.

May 29, 2024
·
2 min read
·
Kate Goodwin
BioMidwest

Top 5 Companies Hiring in Illinois

Looking for a biopharma job in Illinois? Check out these top five companies hiring life sciences professionals like you.

May 29, 2024
·
1 min read
·
Angela Gabriel
Drug Development

Insmed Stock Surges After Brensocatib Aces Phase III Lung Disease Study

In a late-stage trial, Insmed’s small molecule DPP1 inhibitor cut yearly exacerbation rates by around 20% in bronchiectasis patients, according to topline data.

May 29, 2024
·
2 min read
·
Tristan Manalac